Press releases
Bulletin from the Annual General Meeting
2 November, 2026Today, November 2, 2026, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority. Resolution on adoption of the income statement and […]
Interim report 1 July – 30 September 2026
29 October, 2026First quarter summary, July – September 2026 • Net sales amounted to MSEK 0.0 (0.0) • Operating profit amounted to MSEK -1.5 (-1.3) • Earnings per share* SEK -0.08 (-0.07) […]
DexTech Medical brings forward the publication of the interim report
27 October, 2026DexTech Medical AB (publ) announces that the company’s interim report for the first quarter 2026/2027 will be published on Thursday, October 29, 2026, instead of the previously communicated date of […]
DexTech Medical’s myeloma study, study report (CSR) completed, results very positive
27 October, 2026The Clinical Study Report (CSR) has been completed and the preliminary results previously announced have been confirmed. This means that no serious adverse events (SAEs) have been noted and that […]
DexTech: Invitation to open Annual General Meeting and notice
5 October, 2026On Monday, November 2, 2026, DexTech Medical AB (“DexTech”) will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, […]
DexTech Medical AB: Annual Report 2025-07-01 – 2026-06-30
22 September, 2026The Board of Directors and the CEO of Dextech Medical AB (DexTech), org.nr. 556664-6203, with its registered office in Stockholm, hereby submits the Annual Report for the financial year 2025-07-01 […]
Year-end report 1 July 2025 – 30 June 2026
31 August, 2026Fourth quarter summary, April – June 2026 Net sales amounted to MSEK 0.0 (0.0) Operating profit amounted to MSEK -1.9 (-1.6) Earnings per share* SEK -0.10 (-0.08) Clinical highlights […]
DexTech Medical’s myeloma study fully recruited, preliminary results very positive
4 June, 2026The study was conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment has lasted for a total of 14 weeks with 2 doses per month. Three dose […]
Interim Report 1 July 2025 – 31 March 2026
5 May, 2026Summary of the third quarter (2026-01-01 – 2026-03-31) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.7 million (-1.3) Earnings per share* SEK -0.09 (-0.07) […]
Half-year report July 1 – December 31, 2025
25 February, 2026Summary of the second quarter (2025-10-01 – 2025-12-31) Net sales amounted to MSEK 0 (0.0) Operating profit/loss amounted to MSEK -1.7 (-1.1) Earnings per share* SEK -0.09 (-0.05) More than […]